A Multicenter Study Assessing the Optimal Anticoagulation Strategies in COVID-19 Critically Ill Patients with New-Onset Atrial Fibrillation: Balancing Effectiveness and Safety
Khalid Al Sulaiman,Ohoud Aljuhani,Ghazwa Korayem,Ali Altebainawi,Aisha Alharbi,Mai Alalawi,Hala Joharji,Rand Almohsen,Rawa Faden,Nada Alotaibi,Bdour Alshalawi,Nasser Alkhushaym,Fai Alanazi,Ashwaq Alharbi,Aisha Alqarni,Shahad Samkari,Bader Alharbi,Nura Alshehab,Rawan Alshehri,Ramesh Vishwakarma
DOI: https://doi.org/10.2147/ijgm.s484472
IF: 2.145
2024-11-28
International Journal of General Medicine
Abstract:Khalid Al Sulaiman, 1– 5, &ast Ohoud Aljuhani, 6 Ghazwa B Korayem, 7, &ast Ali F Altebainawi, 8, 9 Aisha Alharbi, 10, 11 Mai Alalawi, 10, 11 Hala Joharji, 12– 14 Rand Abdullah Almohsen, 15 Rawa M Faden, 2 Nada Alotaibi, 15 Bdour S Alshalawi, 16 Nasser Alkhushaym, 17 Fai F Alanazi, 2 Ashwaq Alharbi, 18 Aisha Alqarni, 7 Shahad Samkari, 7 Bader Alharbi, 19 Nura Alshehab, 19 Rawan A Alshehri, 2 Ramesh Vishwakarma 20 1 Pharmaceutical Care Department, King Abdulaziz Medical City, Riyadh, Saudi Arabia; 2 College of Pharmacy, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia; 3 King Abdullah International Medical Research Center-King Saud Bin Abdulaziz University for Health Sciences, Ministry of National Guard – Health Affairs, Riyadh, Saudi Arabia; 4 Saudi Critical Care Pharmacy Research (SCAPE) Platform, Riyadh, Saudi Arabia; 5 Saudi Society for Multidisciplinary Research Development and Education (SCAPE Society), Riyadh, Saudi Arabia; 6 Department of Pharmacy Practice, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia; 7 Department of Pharmacy Practice, College of Pharmacy, Princess Nourah Bint Abdulrahman University, Riyadh, 11671, Saudi Arabia; 8 Pharmaceutical Care Services, King Salman Specialist Hospital, hail Health Cluster, Ministry of Health, Hail, Saudi Arabia; 9 Department of Clinical Pharmacy, College of Pharmacy, University of Hail, Hail, Saudi Arabia; 10 Pharmaceutical Care Department, King Abdulaziz Medical City, Jeddah, Saudi Arabia; 11 King Abdullah International Medical Research Center-King Saud Bin Abdulaziz University for Health Sciences, Ministry of National Guard – Health Affairs., Jeddah, Saudi Arabia; 12 Organ Transplant Center of Excellence, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia; 13 College of Pharmacy, Alfaisal University, Riyadh, Saudi Arabia; 14 Dr. Sulaiman Alhabib Medical Group, Riyadh, Saudi Arabia; 15 College of Pharmacy, University of Shaqra, Al Dawadmi, Saudi Arabia; 16 College of Pharmacy, King Saud University, Riyadh, Saudi Arabia; 17 Pharmaceutical Care Services, Royal Commission Hospital, Jubail, Saudi Arabia; 18 College of Pharmacy, Qassim University, Qassim, Saudi Arabia; 19 Pharmacy Services Department, Johns Hopkins Aramco Healthcare, Dhahran, Saudi Arabia; 20 Norwich Medical School, University of East Anglia, Norwich, UK &astThese authors contributed equally to this work Correspondence: Ghazwa B Korayem, Department of Pharmacy Practice, College of Pharmacy, Princess Nourah bint Abdulrahman University, P.O.Box 84428, Riyadh, 11671, Saudi Arabia, Tel +966504161649, Email Purpose: To evaluate the effectiveness and safety of anticoagulation regimens in COVID-19 critically ill patients with new-onset Atrial fibrillation (Afib) during their intensive care unit (ICU) stays. Methods: A multicenter, retrospective cohort study included critically ill patients with COVID-19 admitted to the ICUs. Patients with new-onset Afib were categorized into two groups based on anticoagulation doses (Prophylaxis vs Treatment). The primary outcome was the bleeding rate; other outcomes were considered secondary. Logistic, negative binomial regression, and Cox proportional hazards regression analyses were applied as appropriate after PS matching. Results: A total of 107 patients were eligible. After PS matching (1:1 ratio), 56 patients were included in the final analysis. A higher odd for major and minor bleeding were observed in the patients who received treatment doses of anticoagulation; however, it did not reach the statistically significant (OR 1.46; 95% CI 0.29, 7.42; P =0.65 and OR 2.04; 95% CI 0.17, 24.3; P =0.57, respectively). The hospital length of stay and in-hospital mortality showed no differences between the two groups (beta coefficient − 0.00; CI − 0.38, 0.37; P =0.99 and HR 1.12, 95% CI 0.58– 2.14; p = 0.74, respectively). On the other hand, patients in the treatment group had a statistically significant higher requirement of RBCs transfusion than patients who received a prophylaxis dose (beta coefficient 1.17; 95% CI 0.11, 2.22, P= 0.03). Conclusion: The use of treatment anticoagulation doses in COVID-19 critically ill patients with new-onset Afib did not show better effectiveness over prophylactic anticoagulation doses; however, patients who receiv -Abstract Truncated-
medicine, general & internal